Tiny study probes why islet transplants prevent low blood sugar
NCT ID NCT03079921
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how the nervous system helps control blood sugar in people with type 1 diabetes who had islet cell transplants. Nine participants received drugs that block nerve signals or a placebo during controlled low blood sugar experiments. The goal was to learn whether nerve or hormonal signals are more important for protecting against hypoglycemia after transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Phentolamine and Propranolol
What this could lead to
If successful, this study could help improve understanding of how islet transplants protect against dangerously low blood sugar.
What could go wrong
This is a very small, early-phase study with only 9 participants, so results may not apply broadly. The drugs used are for temporary blockade, not treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE1DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism
Philadelphia, Pennsylvania, 19104, United States